Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

The new FDA-approved weight loss medicines have changed the game for people with obesity, offering millions of Americans a ...

Injectable drugs like Ozempic and Wegovy may be new to most of the world, but the science behind them are familiar to those in the health field.

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

One quick online search or scroll through social media and you'll find an endless amount of weight loss advice.

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Shares of Delta Air Lines Inc. dropped more than 9% after hours Monday after the airline slashed its current-quarter estimates, seeing trouble ahead for demand for its domestic flights.